Thrombolytic eligibility

被引:1
作者
Ellis, CJ [1 ]
French, JK
White, HD
机构
[1] Auckland Hosp, Dept Med, Auckland, New Zealand
[2] Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand
[3] Univ Auckland, Auckland 1, New Zealand
来源
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE | 1998年 / 28卷 / 04期
关键词
thrombolytic therapy; thrombolytic eligibility; thrombolytic rates; myocardial infarction;
D O I
10.1111/j.1445-5994.1998.tb02103.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Fibrinolytic Therapy Trialists' Collaborative Group has demonstrated that patients without clear contraindications who present with ischaemic chess pain within 12 hours of the onset of symptoms and who have ST segment elevation or bundle branch block on their electrocardiogram (ECG), will benefit from thrombolytic therapy. Therefore the treatment of patients presenting with ischaemic chest pain is guided by the initial EGG. This paper addresses the question of thrombolytic eligibility in several subsets of patients who may benefit from treatment. It also explores the data which confirm the benefit for patients presenting with an inferior myocardial infarction and for those presenting from six-la hours after the onset of symptoms. In conclusion, thrombolytic therapy should Mot be routinely withheld from diabetic or elderly patients, menstruating women and patients who have had cardiopulmonary resuscitation.
引用
收藏
页码:518 / 524
页数:7
相关论文
共 48 条
[1]  
[Anonymous], 1990, LANCET, V336, P65
[2]  
[Anonymous], 1988, LANCET, V2, P349
[3]  
[Anonymous], 1986, LANCET, V1, P397
[4]   INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].
APPLEBY, P ;
BAIGENT, C ;
COLLINS, R ;
FLATHER, M ;
PARISH, S ;
PETO, R ;
BELL, P ;
HALLS, H ;
MEAD, G ;
DIAZ, R ;
PAOLASSO, E ;
PAVIOTTI, C ;
ROMERO, G ;
CAMPBELL, T ;
OROURKE, MF ;
THOMPSON, P ;
LESAFFRE, E ;
VANDEWERF, F ;
VERSTRAETE, M ;
ARMSTRONG, PW ;
CAIRNS, JA ;
MORAN, C ;
TURPIE, AG ;
YUSUF, S ;
GRANDE, P ;
HEIKKILA, J ;
KALA, R ;
BASSAND, JP ;
BOISSEL, JP ;
BROCHIER, M ;
LEIZOROVICZ, A ;
BRUGGEMANN, T ;
KARSCH, KR ;
KASPER, W ;
LAMMERTS, D ;
NEUHAUS, KL ;
MEYER, J ;
SCHRODER, R ;
VONESSEN, R ;
SARAN, RK ;
ARDISSINO, D ;
BONADUCE, D ;
BRUNELLI, C ;
CERNIGLIARO, C ;
FORESTI, A ;
FRANZOSI, MG ;
GUIDUCCI, D ;
MAGGIONI, A ;
MAGNANI, B ;
MATTIOLI, G .
LANCET, 1994, 343 (8893) :311-322
[5]   SIGNIFICANCE OF DIABETES-MELLITUS IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION RECEIVING THROMBOLYTIC THERAPY [J].
BARBASH, GI ;
WHITE, HD ;
MODAN, M ;
VANDEWERF, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (03) :707-713
[6]   INFERIOR MYOCARDIAL-INFARCTION - HIGH-RISK SUBGROUPS [J].
BERGER, PB ;
RYAN, TJ .
CIRCULATION, 1990, 81 (02) :401-411
[7]   THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) TRIAL, PHASE-I - A COMPARISON BETWEEN INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR AND INTRAVENOUS STREPTOKINASE - CLINICAL FINDINGS THROUGH HOSPITAL DISCHARGE [J].
CHESEBRO, JH ;
KNATTERUD, G ;
ROBERTS, R ;
BORER, J ;
COHEN, LS ;
DALEN, J ;
DODGE, HT ;
FRANCIS, CK ;
HILLIS, D ;
LUDBROOK, P ;
MARKIS, JE ;
MUELLER, H ;
PASSAMANI, ER ;
POWERS, ER ;
RAO, AK ;
ROBERTSON, T ;
ROSS, A ;
RYAN, TJ ;
SOBEL, BE ;
WILLERSON, J ;
WILLIAMS, DO ;
ZARET, BL ;
BRAUNWALD, E .
CIRCULATION, 1987, 76 (01) :142-154
[8]   Is thrombolytic therapy really than conventional treatment in acute inferior myocardial infarction? [J].
Ellis, C ;
French, JK ;
White, HD .
HEART, 1996, 76 (03) :291-291
[9]  
ELLIS CJ, 1995, BRIT HEART J, V74, P476
[10]  
*EUR MY INF PROJ G, 1993, NEW ENGL J MED, V329, P385